New hope for brain diseases? early trial tests experimental treatment
NCT ID NCT06671938
Summary
This study is testing the safety and how the body processes a new drug called exidavnemab in people with mild to moderate Parkinson's disease or multiple system atrophy. About 38 participants will receive either the drug or a placebo to see how well it is tolerated. The main goal is to find a safe dose range for future, larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centrum Medyczyne Neuromed Sp. z o.o.
Bydgoszcz, 85-163, Poland
-
Hospital Universitari General de Catalunya
Sant Cugat del Vallès, Barcelona, 08195, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Madrid, 28034, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Andalusia, 41013, Spain
-
Krakowska Akademia Neurologii Sp. Z o.o
Krakow, 31-505, Poland
-
Policlínica Gipuzkoa
San Sebastián, 20014, Spain
Conditions
Explore the condition pages connected to this study.